European equities traded in the US as American depositary receipts were tracking higher late Wednesd

European equities traded in the US as American depositary receipts were edging higher late Wednesday

CEO Abia discusses immunoglobulin growth and Egypt plasma expansion strategy.

Grifols SA (GRFS) reports robust revenue growth and strategic progress, despite facing temporary challenges in key markets.

Grifols (NASDAQ:GRFS) said its second-quarter and first-half results kept the plasma-derived medicines company on track to meet its 2026 objectives, supported by continued growth in immunoglobulins, improving free cash flow and progress in its plasma-sourcing strategy. Chief Executive Officer Nacho

Grifols (BME:GRF) has started dosing patients in two Phase 3 trials for its immunoglobulin therapies, GAMUNEX-C and XEMBIFY, aiming to expand their U.S. labels and potentially broaden future treatment options. See our latest analysis for Grifols. These new Phase 3 trials come as Grifols shares trade at €9.85, with a 90 day share price return of 10.36% but a year to date share price return that has declined 12.05%, and a 1 year total shareholder return that has fallen 19.51%. This suggests...

European equities traded in the US as American depositary receipts started the week slightly higher

European equities traded in the US as American depositary receipts were tracking lower late Thursday

European equities traded in the US as American depositary receipts started the week lower late Monda

European equities traded in the US as American depositary receipts were rising on Wednesday morning,